Frederick W. Thielen

1.2k total citations
24 papers, 274 citations indexed

About

Frederick W. Thielen is a scholar working on Oncology, Economics and Econometrics and Genetics. According to data from OpenAlex, Frederick W. Thielen has authored 24 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Economics and Econometrics and 5 papers in Genetics. Recurrent topics in Frederick W. Thielen's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), CAR-T cell therapy research (3 papers) and Viral-associated cancers and disorders (3 papers). Frederick W. Thielen is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), CAR-T cell therapy research (3 papers) and Viral-associated cancers and disorders (3 papers). Frederick W. Thielen collaborates with scholars based in Netherlands, Austria and United Kingdom. Frederick W. Thielen's co-authors include Silvia Evers, Carin A. Uyl‐de Groot, Wichor M. Bramer, Ghislaine van Mastrigt, Jos Kleijnen, L.T. Burgers, Peter M. Hoogerbrugge, Marie José Kersten, Pieter Sonneveld and Jorge Sierra and has published in prestigious journals such as Blood, PLoS ONE and JAMA Psychiatry.

In The Last Decade

Frederick W. Thielen

21 papers receiving 270 citations

Peers

Frederick W. Thielen
Elaine Yu United States
Eoin McGrath Netherlands
Anna Marie P. Young United States
Elizabeth Cathcart-Rake United States
Rikke Pilsgaard Svendsen Denmark
Asma Dilawari United States
Hilary Pang Canada
Mary M. Bell United States
Timothy Kubal United States
Yi‐Lin Wu Taiwan
Elaine Yu United States
Frederick W. Thielen
Citations per year, relative to Frederick W. Thielen Frederick W. Thielen (= 1×) peers Elaine Yu

Countries citing papers authored by Frederick W. Thielen

Since Specialization
Citations

This map shows the geographic impact of Frederick W. Thielen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick W. Thielen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick W. Thielen more than expected).

Fields of papers citing papers by Frederick W. Thielen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick W. Thielen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick W. Thielen. The network helps show where Frederick W. Thielen may publish in the future.

Co-authorship network of co-authors of Frederick W. Thielen

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick W. Thielen. A scholar is included among the top collaborators of Frederick W. Thielen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick W. Thielen. Frederick W. Thielen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sommer, Iris E., Shiral S. Gangadin, Lieuwe de Haan, et al.. (2025). Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission. JAMA Psychiatry. 83(1). 68–68.
2.
3.
Jager, Agnes, et al.. (2025). Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study. The Breast. 84. 104573–104573. 1 indexed citations
4.
Ruijgrok, Elisabeth J., et al.. (2024). What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency. PharmacoEconomics - Open. 9(2). 207–215. 4 indexed citations
5.
Thielen, Frederick W., et al.. (2024). Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLoS ONE. 19(2). e0293264–e0293264. 2 indexed citations
6.
Leeuwen, Roelof W. F. van, et al.. (2024). The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective. BMC Health Services Research. 24(1). 1322–1322. 1 indexed citations
7.
Thielen, Frederick W., et al.. (2023). Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma. BMC Medical Research Methodology. 23(1). 132–132. 1 indexed citations
8.
Leeneman, B, Hedwig M. Blommestein, Willem E. Fibbe, et al.. (2023). Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease. European Journal Of Haematology. 111(2). 240–246. 1 indexed citations
9.
10.
11.
Thielen, Frederick W., Marie José Kersten, Mels Hoogendoorn, et al.. (2021). Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Review of Anticancer Therapy. 21(12). 1411–1422. 2 indexed citations
12.
Thielen, Frederick W., Marc Koopmanschap, Marie José Kersten, et al.. (2021). Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. HemaSphere. 5(2). e524–e524. 36 indexed citations
13.
Wijnen, Ben, Frederick W. Thielen, Talitha Feenstra, et al.. (2019). Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. Expert Review of Pharmacoeconomics & Outcomes Research. 20(3). 269–279. 12 indexed citations
14.
Houwing, Maite E., Frederick W. Thielen, Anne P.J. de Pagter, et al.. (2019). The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease. Blood. 134(Supplement_1). 1030–1030.
15.
Thielen, Frederick W., Nasuh Büyükkaramikli, Rob Riemsma, et al.. (2018). Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. PharmacoEconomics. 37(8). 975–984. 3 indexed citations
16.
Speetjens, Paula, Frederick W. Thielen, Margreet ten Have, R. de Graaf, & F. Smit. (2017). [Child maltreatment: long-term economic consequences and implications].. PubMed. 58(10). 706–711. 1 indexed citations
17.
Oosten, Liesbeth E.M., Martine E.D. Chamuleau, Frederick W. Thielen, et al.. (2017). Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Annals of Hematology. 97(2). 255–266. 26 indexed citations
18.
Thielen, Frederick W., Margreet ten Have, Ron de Graaf, et al.. (2016). Long-term economic consequences of child maltreatment: a population-based study. European Child & Adolescent Psychiatry. 25(12). 1297–1305. 23 indexed citations
19.
Thielen, Frederick W., Ghislaine van Mastrigt, L.T. Burgers, et al.. (2016). How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert Review of Pharmacoeconomics & Outcomes Research. 16(6). 705–721. 96 indexed citations
20.
Wilson, Louis, et al.. (1991). Monoclonal antibodies to human embryonal carcinoma cells: antigenic relationships of germ cell tumors.. PubMed. 65(2). 180–91. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elaine Yu Breakdown of academic impact, for papers by Eoin McGrath Breakdown of academic impact, for papers by Anna Marie P. Young Breakdown of academic impact, for papers by Elizabeth Cathcart-Rake Breakdown of academic impact, for papers by Rikke Pilsgaard Svendsen Breakdown of academic impact, for papers by Asma Dilawari Breakdown of academic impact, for papers by Hilary Pang Breakdown of academic impact, for papers by Mary M. Bell Breakdown of academic impact, for papers by Timothy Kubal Breakdown of academic impact, for papers by Yi‐Lin Wu
Rankless by CCL
2026